The FTSE 100 opened in positive territory on Monday, rising 0.4% by 07:20 GMT, supported by broad market gains across Europe. The pound edged slightly lower against the dollar but remained above $1.34, down 0.08%. European markets also advanced, with Germany’s DAX gaining 1.1% and France’s CAC 40 up 0.6%.
B&M Shares Sink After Guidance Cut and CFO Exit
Shares of B&M European Value Retail S.A. (LSE:BME) plunged more than 18% after the company cut its FY26 financial outlook due to a £7 million error in overseas freight cost recognition.
B&M now expects Group Adjusted EBITDA (pre-IFRS 16) between £470 million and £520 million for FY26, down from the previous range of £510 million to £560 million announced earlier this month. First-half FY26 EBITDA guidance has also been lowered to approximately £191 million from £198 million.
In a management shake-up, CFO Mike Schmidt announced his intention to step down, with a formal search underway for his successor. Schmidt will remain in his role until a smooth transition is completed.
Plus500 Beats Forecasts with Strong Q3
Plus500 (LSE:PLUS) posted stronger-than-expected Q3 2025 results, driven by robust growth in its U.S. futures business and consistent over-the-counter trading activity.
Revenue came in at $182.7 million, around 10% above consensus estimates of $165 million. Trading income accounted for $161.6 million, while interest income rose sharply to $21.1 million, up from $15 million in each of the previous two quarters. EBITDA reached $82.7 million, delivering a 45% margin — about 5% above implied market expectations, according to Jefferies.
GlobalData Reaffirms FY25 Revenue Outlook
GlobalData Plc (LSE:DATA) reaffirmed that its FY25 revenue is expected to be in line with market forecasts. The company reported 13.5% revenue growth in Q3, supported by an improvement in underlying subscription revenue growth from 1% in the first half to 2% in the third quarter, along with contributions from recent acquisitions.
Enhertu Delivers Positive Results in Breast Cancer Trials
AstraZeneca PLC (LSE:AZN) and Daiichi Sankyo Co., Ltd. (TG:D4S) announced that their cancer therapy Enhertu produced strong outcomes in two pivotal trials for early-stage breast cancer.
The data showed significant efficacy in treating a specific form of early-stage breast cancer, supporting the ongoing development and clinical testing of the drug by both companies.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.
Leave a Reply